摘要
目的:探讨CYP2C19基因多态性对唑吡坦治疗缺血性脑卒中后失眠症的血药浓度及疗效的影响。方法:选取2021年10月至2023年12月东莞市万江医院收治的缺血性脑卒中后失眠症患者60例作为研究对象,按照随机数字表法分为对照组和观察组,每组30例。研究对象均予唑吡坦治疗,对照组采取经验性用药,观察组根据CYP2C19基因多态性检测结果个体化用药。对比分析2组的血药浓度、疗效情况以及治疗前后睡眠障碍评定量表(SDRS)评分。结果:2组的血药浓度比较,差异无统计学意义(P>0.05)。观察组患者治疗后SDRS评分低于对照组,差异有统计学意义(P<0.05)。观察组的总有效率高于对照组,差异有统计学意义(P<0.05)。结论:CYP2C19基因多态性检测在指导唑吡坦治疗缺血性脑卒中后失眠症的个体化用药方面有着良好的价值。
Objective:To investigate the effect of CYP2C19 gene polymorphism on the plasma concentration and efficacy of zolpidem in the treatment of insomnia after ischemic stroke.Methods:A total of 60 patients with post-ischemic stroke insomnia admitted to Dongguan Wanjiang Hospital from October 2021 to December 2023 were selected as the study objects,and were divided into control group and observation group according to random number table method,with 30 cases in each group.All subjects were treated with zolpidem,the control group was treated with empirical medication,and the observation group was treated with individualized medication according to the results of CYP2C19 gene polymorphism.The blood drug concentration,efficacy,and pre-and post-treatment Sleep Disorder Rating Scale(SDRS)scores between the two groups were compared.Results:There was no significant difference in blood concentration between the two groups(P>0.05).The SDRS score of the observation group patients after treatment was significantly lower than control group,the difference was statistically significant(P<0.05).The total effective rate of the observation group was higher than control group,the difference was statistically significant(P<0.05).Conclusion:CYP2C19 gene polymorphism detection has a good value in guiding the individualized medication of zolpidem in the treatment of insomnia after ischemic stroke.
作者
庄建伟
朱振武
雷东来
ZHUANG Jianwei;ZHU Zhenwu;LEI Donglai(Department of Neurology,Wanjiang Hospital,Dongguan 523040,China)
出处
《世界睡眠医学杂志》
2024年第6期1218-1220,共3页
World Journal of Sleep Medicine
基金
东莞市社会发展科技项目(20211800901852)。
